Edinburgh is the best-supplied city in Scotland for this treatment, and the one where the Scottish anomaly matters most. The essential fact is that a devolved medicines decision went the other way here: where NICE said no, the Scottish Medicines Consortium said yes with restrictions, so an NHS-funded esketamine route exists for Edinburgh patients that does not exist in England, Wales or Northern Ireland. On top of that national layer, the city itself holds a verified private clinic and a recruiting trial site. This guide sets out all three doors and how to open each; the full national picture is in our Scotland guide.
TL;DR The NHS route in Edinburgh is esketamine (Spravato), accepted by the SMC for restricted use in treatment-resistant depression and delivered via psychiatrist assessment and NHS Lothian's health board arrangements — start by asking your psychiatrist, with a written treatment history in hand. Racemic ketamine infusions are not routinely funded by the NHS anywhere in the UK, so infusions and ketamine-assisted psychotherapy are private and self-pay: Eulas Clinics in Edinburgh publishes a six-week programme from around £6,000, and the wider UK range is roughly £300–800 per infusion. A trial site in the city is recruiting and free.
The routes at a glance
| NHS esketamine (Scotland) | Private KAP in Edinburgh | NHS trust, self-funded (Oxford) | Clinical trial | |
|---|---|---|---|---|
| What it is | Spravato nasal spray under supervision, alongside a continuing oral antidepressant | Off-label ketamine with preparation and integration therapy, as a structured programme | Off-label IV ketamine inside an NHS trust's own service | Study medicine under research protocol |
| Who can use it | Treatment-resistant depression assessed by a psychiatrist under SMC restrictions and health board arrangements | Self-referral is widely accepted, but suitability is established by a full clinical assessment — diagnosis and severity, previous treatment, comorbidity, current medicines and substance use, risk and consent — not by passing an initial screen | Anyone with a referral letter from a GP or psychiatrist, subject to the service's intake rules | Study-specific criteria; strict screening |
| Cost | Covered by NHS Scotland | Programme from ~£6,000; UK-wide infusion range £300–800 | £265 per infusion and per initial assessment; budget ~£3,000/year | Free |
| How to start | Ask your psychiatrist about the pathway in NHS Lothian | Contact the clinic directly | GP or psychiatrist referral letter, then an assessment usually held online | Registry search plus screening |
The NHS route: esketamine, via your psychiatrist
The Scottish Medicines Consortium accepted esketamine (SMC2258) for restricted use in treatment-resistant depression under a patient access scheme, implemented through the health boards. NICE, by contrast, did not recommend it in TA854 on cost-effectiveness grounds, a decision that applies in England and Wales and which Northern Ireland endorsed. The result is a genuine postcode difference within one licensed medicine — the detail is in our UK reimbursement guide — and Edinburgh is on the funded side of the line.
What the restriction turns on is documented treatment resistance — generally, an inadequate response to at least two different antidepressant treatments of adequate dose and duration during the current moderate-to-severe episode. Under the licence, esketamine is then given alongside a continuing oral SSRI or SNRI, and failing two treatments does not by itself guarantee suitability: the assessment weighs diagnosis, comorbidity, current medicines and risk as well. Assessment is by a psychiatrist, and delivery depends on your local health board's arrangements — for Edinburgh, NHS Lothian. Two practical implications follow. First, your GP is not the decision-maker but is the door: a referral into secondary care, plus a printout of your medication history, is the useful first ask. Second, the written treatment history — every antidepressant tried in the current episode, with dose, duration and outcome — carries the case. Bring it; it counts for more than anything you say in the room.
If esketamine is approved for you, the sessions are supervised: you self-administer the spray in the clinic, blood pressure is checked before the dose and again at about 40 minutes, and staff observe for sedation, dissociation and other adverse effects until you are clinically stable — roughly two hours is a typical observation period, not a fixed discharge point. You continue an oral antidepressant alongside, and you do not drive or do anything hazardous until the following day, after a restful sleep. Our preparation checklist covers the day in detail.
Safety in brief. Common adverse effects of supervised esketamine include dizziness, dissociation, nausea, headache, sleepiness, altered taste, vertigo, vomiting and a transient rise in blood pressure; rare respiratory depression has been reported. The licence rules out treatment where a blood-pressure or intracranial-pressure rise would pose a serious risk — aneurysmal vascular disease, a previous bleed in the brain, a recent cardiovascular event — and calls for caution with psychosis, a history of mania or bipolar disorder, substance-misuse risk, pregnancy, and interacting medicines such as sedatives or those that raise blood pressure. Screening and monitoring exist to manage exactly these; disclose everything at assessment.
The private option in the city
The NHS route is for esketamine specifically. Racemic ketamine — the generic anaesthetic given as an intravenous infusion — has never been appraised for routine NHS commissioning anywhere in the UK, because its use for depression is off-label. The NHS pilots of racemic ketamine that do exist run at Oxford Health and Central and North West London NHS Foundation Trusts (Magnetar/Blossom reimbursement report, 2025), both in England and reached through NHS referral rather than direct booking. So in Edinburgh, infusions and ketamine-assisted psychotherapy mean the private market, on UK terms: roughly £300–800 per infusion, with London typically around £595, and full KAP programmes from about £6,000 for six weeks.
In our directory, the verified private option in the city is Eulas Clinics in Edinburgh, a ketamine-assisted psychotherapy provider that also lists sites in London and Manchester and publishes a six-week programme from around £6,000, with payment plans from £177 per month (clinic pricing page, checked July 2026). Whether the therapy layer in a KAP programme is worth the difference over bare infusions is a real clinical question, not a settled one: a 2026 systematic review found a heterogeneous evidence base with few randomised trials and few psychotherapy-control groups, so the added benefit of preparation and integration therapy remains uncertain, and it should not be treated as a required component of ketamine treatment. You can compare everything we list on the Edinburgh directory page and across providers in the United Kingdom; our UK cost comparison collects the published figures.
One cross-border option is worth pricing before you commit. Oxford Health NHS Foundation Trust runs a self-funded ketamine service inside the NHS at £265 per infusion and per initial psychiatrist assessment, with £125 per scheduled review, open to patients with a referral letter from a GP or psychiatrist subject to its intake rules — the assessment itself usually happens online, and the service suggests budgeting around £3,000 per year. For an Edinburgh patient an induction course at those prices, travel included, may still undercut a private programme at home — recent consensus describes roughly four to six infusions over two to four weeks as common practice rather than a licensed standard, and Oxford itself plans three to six over three to six weeks, individualised on response.
Whichever you choose, verify before paying. Independent clinics in Scotland are regulated by the Scottish equivalent of the CQC rather than by the CQC itself, so check the clinic's entry on the relevant national register, check the prescriber on the GMC register, get the full course cost in writing, and ask what maintenance costs after the induction. The full checklist is in our clinic-choice guide. And ask what happens after the induction: esketamine has a defined induction-and-maintenance schedule with periodic review of continued benefit; IV ketamine has no licensed UK schedule for depression, so any continuation or maintenance is individualised. Either way, expect symptom measurement and an agreed decision point for stopping, continuing or reconsidering treatment — agreed before the course starts, not improvised at its end.
The research route
If cost is the constraint, trials are free by definition — legitimate studies never charge, and many reimburse travel. Edinburgh has its own recruiting site: our directory lists NHS Research Scotland in Edinburgh as a site recruiting for NCT06793397, Cybin's Phase 3 study of the deuterated psilocin analogue CYB003 in major depressive disorder — a serotonergic psychedelic, not ketamine — with a second Scottish site at Queen Elizabeth University Hospital in Glasgow. Across the UK, 67 studies are tracked and 12 are active, spanning psilocybin, ketamine, DMT and esketamine.
Screening is strict and enrolment is never guaranteed, so treat trials as an option to check rather than a plan to rely on. Our trials guide explains how phases, placebo and consent work and how to search the registries. The national picture — including Glasgow, the NHS pilots and every legal route — is in our Scotland guide and our UK access guide.
Frequently asked questions
Can I get ketamine therapy on the NHS in Edinburgh?
You can get esketamine (Spravato) on the NHS in Edinburgh if a psychiatrist assesses you as meeting the SMC restrictions for treatment-resistant depression and NHS Lothian provides the service. Racemic ketamine infusions are not routinely NHS-funded in Scotland or anywhere else in the UK; the NHS ketamine pilots are in England.
How do I start the NHS esketamine route in Edinburgh?
Ask your psychiatrist directly about the esketamine pathway in NHS Lothian — do not assume the England picture applies to you. If you are not currently under a psychiatrist, ask your GP for a referral into secondary care and take a written history of every antidepressant tried in the current episode with dose, duration and outcome.
What does private ketamine therapy cost in Edinburgh?
The verified Edinburgh provider, Eulas Clinics, publishes a six-week ketamine-assisted psychotherapy programme from around £6,000; the wider UK market runs roughly £300–800 per infusion. Ask for the full course cost in writing rather than a per-session price, and compare it against the £265 per infusion charged by the NHS trust service in Oxford, which accepts self-funded referrals from outside its area.
Is Spravato the same as ketamine infusions?
No. Spravato is esketamine — the S-enantiomer of the ketamine molecule — given as a nasal spray under its own EU and UK licence for treatment-resistant depression; racemic ketamine contains both R- and S-enantiomers and is generally given intravenously, off-label, when used for depression. Dosing schedules, evidence, monitoring and maintenance pathways differ, and the head-to-head evidence is mostly observational — it does not establish that the two are interchangeable or that one is generally superior. See our side-by-side comparison.
Are there depression or psychedelic trials in Edinburgh?
Yes — though the active Edinburgh study is not a ketamine trial. An NHS Research Scotland site in the city is recruiting for a Phase 3 depression study of CYB003, a deuterated psilocin analogue (a serotonergic psychedelic, not ketamine or esketamine); UK-wide, the trial scene does include ketamine and esketamine studies. Participation is free, screening is strict, and enrolment is never guaranteed.
Sources
- SMC: Esketamine (Spravato) advice — SMC2258
- NICE TA854: Esketamine nasal spray for treatment-resistant depression — recommendations
- Oxford Health NHS FT: Interventional Psychiatry Service pricing
- Oxford Health NHS FT: Ketamine TRD service
- Eulas Clinics: ketamine therapy pricing
- The Burlington Clinic: ketamine therapy cost in London
- ClinicalTrials.gov: NCT06793397 — CYB003 Phase 3 in major depressive disorder
- Blossom: United Kingdom country report
- Reimbursement Pathways for Psychedelic Therapies in Europe — Magnetar Access × Blossom (2025)
- Spravato — UK Summary of Product Characteristics (SmPC), sections 4.1–4.8
- Mathai et al. (2026), Journal of Affective Disorders — ASKP3 consensus guidelines on intravenous ketamine for depressive disorders
- Veraart et al. (2026), Clinical Psychology Review — ketamine-assisted psychotherapies: historical overview and systematic review
This guide is for general information only and is not medical advice, a diagnosis, or a recommendation of any treatment. Regulations and prices change; always verify a provider's current registration with the relevant regulator, confirm fees in writing, and discuss your options with a licensed clinician who knows your history. If you are in crisis, contact your local emergency number or a crisis line immediately.
This guide awaits review by a licensed medical professional.